Clinical trial
Safety Study of NHL With 90Y-hLL2 IgG
NCT00421395 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00421395 |
|---|---|
| Title | Safety Study of NHL With 90Y-hLL2 IgG |
| Official title | Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | NHL, B-cell NHL, Non-Hodgkins Lymphoma |
| Intervention type | Biological |
| Interventions | 90Y-hLL2 |
| Enrollment | 59 |
| Start date | Aug 1, 2002 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jan 12, 2007 |
| Last update posted | Aug 16, 2021 |
| Countries | France, Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: